Expression of placenta growth factor (PIGF) in non-small cell lung cancer (NSCLC) and the clinical and prognostic significance

Abstract

Background: Placenta growth factor (PlGF) is a member of the vascular endothelial growth factor (VEGF) family. Over-expression of PlGF is known to be associated with pathological angiogenesis. This study examined PlGF expression at protein and message levels in non-small cell lung cancer (NSCLC), in which no reports on the significance of PlGF expression is available to date. Patients and methods: We used immunohistochemistry to assess the PlGF protein and correlated PlGF with microvessel density (MVD), as well as clinical outcome in patients with NSCLC tumours (n=91). In addition, we applied a real time quantitative PCR assay using SYBR Green chemistry to measure PlGF mRNA in normal lung tissues and NSCLC tumours. Results: PlGF was positively stained mainly in cytoplasm of lung cancer cells. High level staining of PlGF was found in 38.5% NSCLC patients. A high level of MVD in NSCLC was found in 42.9% of cases. Tumours with high level and low level PlGF staining had a significantly different MVD (26.69 vs. 20.79, respectively, p=0.003). Using both univariate and multivariate analyses, PlGF was found to be an independent prognostic factor. Real time PCR analysis revealed that PlGF mRNA was higher in the cancer tissue than normal tissue (0.95±0.19 vs. 0.57±0.24; p<0.005) and that PlGF mRNA was significant higher in III-IV stage patients than I-=II stage patients (1.03±0.20 vs 0.80±0.17;p=0.011). Conclusion: PlGF expression is significantly more in NSCLC tumour tissues than in matched normal tissues. It has a significant positive association with MVD and is an independent factor for NSCL patients. PlGF may have a pivotal role in NSCLC development and disease progression. © 2005 Zhang et al; licensse BioMed Central Ltd.